Palvella Therapeutics, Inc (NASDAQ:PVLA) — Market Cap & Net Worth
Market Cap & Net Worth: Palvella Therapeutics, Inc (PVLA)
Palvella Therapeutics, Inc (NASDAQ:PVLA) has a market capitalization of $965.15 Million ($965.15 Million) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9262 globally and #2456 in its home market, demonstrating a -0.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Palvella Therapeutics, Inc's stock price $126.84 by its total outstanding shares 11836490 (11.84 Million). Analyse Palvella Therapeutics, Inc cash flow conversion to see how efficiently the company converts income to cash.
Palvella Therapeutics, Inc Market Cap History: 2024 to 2026
Palvella Therapeutics, Inc's market capitalization history from 2024 to 2026. Data shows growth from $142.04 Million to $1.50 Billion (0.00% CAGR).
Index Memberships
Palvella Therapeutics, Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.04% | #253 of 976 |
Weight: Palvella Therapeutics, Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Palvella Therapeutics, Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Palvella Therapeutics, Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PVLA by Market Capitalization
Companies near Palvella Therapeutics, Inc in the global market cap rankings as of May 3, 2026.
Key companies related to Palvella Therapeutics, Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Palvella Therapeutics, Inc Historical Marketcap From 2024 to 2026
Between 2024 and today, Palvella Therapeutics, Inc's market cap moved from $142.04 Million to $ 1.50 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.50 Billion | +21.18% |
| 2025 | $1.24 Billion | +772.25% |
| 2024 | $142.04 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Palvella Therapeutics, Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $965.15 Million USD |
| MoneyControl | $965.15 Million USD |
| MarketWatch | $965.15 Million USD |
| marketcap.company | $965.15 Million USD |
| Reuters | $965.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to tr… Read more